LXEO Lexeo Therapeutics Inc

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:

	H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET
	Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 1:25 PM ET
	Cantor 2024 Global Healthcare Conference on Wednesday, September 18, 2024 at 11:30 AM ET
	Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:30 PM ET

The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.

About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Media Response:media@lexeotx.com

Investor Response:Stephen Jasper(858) 525-2047stephen@gilmartinir.com